Constitutive activation of the JAK2 signaling network is a hallmark of MPN and has led to the clinical use of JAK2 inhibitors as standard treatment in MF and refractory PV [3, 34–36]. This evidence concerns the gene JAK2 and myeloproliferative neoplasm.